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Background: Cerebral vasculopathy have been described in Fabry disease, in which altered cerebral blood flow,
vascular remodelling or impairment of endothelial function could be involved. Our study aims to evaluate these
three possibilities in a group of Fabry patients, and compare it to healthy controls.
Methods: Cerebral hemodynamics, vascular remodelling and systemic endothelial function were investigated in 10
Fabry patients and compared to data from 17 healthy controls. Transcranial Doppler was used to study blood flow
velocity of intracranial arteries and cerebral vasomotor reactivity. For the study of vascular remodelling and
endothelial function, intima-media thickness of common carotid arteries, flow-mediated dilation in brachial artery
and serum levels of soluble VCAM-1, TNF-α, high-sensitive CRP and IL-6 were measured. Differences between
groups were evaluated using appropriate tests.
Results: No relevant differences were observed in cerebral hemodynamic parameters, intima-media thickness or
flow-mediated dilation. There was a trend for low serum levels of IL-6 and high serum levels of TNF-α and
high-sensitive CRP in Fabry patients; plasma concentrations of soluble VCAM-1 were significantly higher in Fabry
disease patients than in healthy volunteers (p = 0.02).
Conclusions: In our sample, we did not find relevant alterations of cerebral hemodynamics in Fabry disease
patients. Increased levels of plasmatic endothelial biomarkers seem to be the most important feature indicative
of possible vascular dysfunction in Fabry disease patients.
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Anderson Fabry disease (FD) (OMIM 301500) is an X-linked
inherited sphingolipid storage disorder caused by deficiency
of lysosomal enzyme alpha-galactosidase A (GLA). This
illness is characterized by progressive accumulation of
glycosphingolipids, mainly globotriaosylceramide (Gb3),
in lysosomes in a variety of cell types, including renal
cells, myocardial cells, heart valve fibrocytes, nervous sys-
tem cells, and endothelial cells of blood vessels [1-7].
FD is associated with a broad range of clinical symptoms
[3], including pain and paresthesias in the extremities, sen-
sorineural hearing loss, angiokeratoma, corneal and lenticu-
lar opacities, hypohidrosis, cardiac and renal dysfunction,* Correspondence: tsmtsm08@yahoo.es
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reproduction in any medium, provided the orgastrointestinal symptoms, TIA and stroke [3,5,7]. The
disease can be diagnosed measuring alpha-galactosidase
A activity in leukocytes or plasma and analyzing geno-
type (mutation analysis of GLA gene). Once the diagnosis
is made, FD can be treated with enzyme replacement
therapy (ERT), commercially available since 2001 [3,5,8].
Monitoring of FD progression is based on clinical, radio-
logical, and laboratory assessments [9].
Cerebral micro- and macro-angiopathy are hallmarks
of FD [6] and cerebrovascular ischemic events (brain
infarctions or transient ischemic attacks) are present in
over 25% of patients, and the frequency increases with
age. In fact, it is probable that stroke could be the first
manifestation of the disease in some patients [10] and one
of the most common clinical manifestations in women
[11]. An etiology of each single event is hard to identify,
and it is likely to be mixed even in the same patient atLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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arterio-arterial embolism and cardiogenic embolism are
all potential mechanisms [8].
Of note, despite its potential severity, there is currently
no early marker for cerebrovascular risk that allows
optimization of the treatment of patients affected by FD
(either hemizygotic males or heterozygotic females), nor
is it possible to investigate the value of ERT in reducing
that risk. Among possible markers to cerebral impair-
ment in FD, parameters of brain hemodynamics, with
controversial results, have been studied [12-15].
In this context, the aim of our study was to investi-
gate the potential presence of alterations in cerebral
hemodynamics (using transcranial Doppler to measure
brain blood flow velocities and cerebral vasomotor re-
activity), as well as the existence or not of vascular
remodelling (measuring intima-media thickness and the
distance between adventitial layers in common carotid
arteries) and the presence of endothelial dysfunction
(using the reactive brachial hyperaemia test and levels of
endothelium released markers) in patients of both sexes
diagnosed of FD in comparison with healthy volunteers.Methods
A total of 27 subjects over age 18 years and agreeing to
take part in the study were recruited and centrally studied
in our neurosonology laboratory. The sample included 17
age and sex-matched healthy volunteers (12 females and
5 males, age range 18–61 years) and 10 patients diagnosed
with FD (6 females and 4 males, age range 18–61 years).
All patients carried a mutation associated with a classic
phenotype of FD. All males had a low or very low GAL
enzyme activity in plasma (between 1–15 nmol/h/mg). In
women, the diagnosis had been made through the iden-
tification of a pathogenic GLA mutation on molecular
genetic testing, although in three of the six women en-
zymatic activity was also low, less than 15 nmol/h/mg. In
the Fabry group, all males and two females were receiving
ERT. Three males were taking this treatment for 5 years,
one since 7 years and one for 3 years. One of the females
took the treatment for 5 years and the other female since
one year before the study measurements.
All patients with FD were selected from the Spanish
Fabry Outcome Survey (FOS) database. The work was part
of a wider project, within an educational grant awarded to
the Department of Neurology of Albacete General Hospital.
The study complied with the ethical principles of the
Spanish Fabry Outcome Survey Project protocol and was
approved by the Albacete General Hospital Research
Ethics Committee. All patients as well as control subjects
provided informed consent.
Exclusion criteria included the existence of an unstable
cardiovascular disorder, previous cerebrovascular symptoms,anemia or severe obstructive pulmonary disease and the
absence of a transcranial sonographic window.
For the study of brain hemodynamics, both determin-
ation of blood flow in brain arteries and measurement of
cerebral vasomotor reactivity (CVR) were conducted using
Transcranial Doppler (TCD Box, Compumedics DWL,
Singen, Germany). We measured the blood flow velocity
of the main intracranial arteries: the right and left mid-
dle cerebral arteries (Vmca), anterior cerebral arteries
(Vaca), posterior cerebral arteries (Vpca) and the basilar
artery (Vbas). Gosling`s pulsatility index (PI) of these 7
intracranial arteries was calculated according to the
following formula: PI = (Vmax –Vmin)/Vmean. CVR
was also measured by TCD using as trigger stimuli a
voluntary apnoea, (the so-called breath-holding test).
We calculated the percentage of increase of blood flow
velocity in the right middle cerebral artery after a vol-
untary 25-seconds apnea, as previously described [16].
In order to assess the existence of a potential vascular
remodelling, we measured the intima-media thickness
(IMT) of common carotid arteries (MyLab 25 Gold,
Esaote, Geneve, Italy) as previously reported [17] and
also the distance between adventitial layers of both com-
mon carotid arteries. We estimated the endothelial func-
tion performing the post-ischemic brachial vasodilation
test (also known as flow-mediated brachial vasodilation
or brachial hyperaemic vasodilation test), expressed as
percentage of dilation in 60 seconds [18] and serum levels
of biomarkers related with inflammation and endothelial
dysfunction: soluble vascular cell adhesion molecule-1
(sVCAM-1), tumor necrosis factor-α (TNF-α), high-
sensitive CRP (hs-CRP) and interleukin-6 (IL-6). Plasma
levels of sVCAM-1 (ng/mL), TNF-α and IL-6 (pg/mL) were
determined using specific cytokine antibodies (Biosource
Europe, S.A., Belgium), while high-sensitive C-reactive
protein (hs-CRP) (range 0.05 – 170 mg/L) was measured
using an immunoturbidimetric assay (Tina-quant® C-
reactive protein (latex) high sensitive assay, Roche, USA).
Statistical analysis
Data were analysed with SPSS for Windows (version 17.0).
Continuous variables were presented as mean ± SD.
Comparations between Fabry patients and controls were
performed using the Mann–Whitney rank sum test for
non-normally distributed data and the t-test for normally
distributed variables. Values of p <0.05 were considered
significant.
Results
Demographic and baseline characteristics were similar
in both groups. Age of participants was 37,5 ± 13,4 in
FD patients and 37,7 ± 14,0 in control subjects (mean
age ± SD). There were no relevant differences regarding
classical vascular risk factors (arterial hypertension, diabetes,
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trol group had arterial hypertension, while four patients
with FD versus two subjects of the control group suffered
dyslipidemia. Of note, only one patient had advanced kidney
disease, in whom the lowest α-Gal A activity was detected.Brain hemodynamics
No differences were observed between groups in the
flow velocities of the brain arteries or in their PI, nor in
the anterior group (middle and anterior cerebral arteries)
neither in the posterior ones (posterior and basilar
arteries) (Table 1).
In the evaluation of cerebral vasomotor reactivity
(apnea test), we only observed a tendency toward aTable 1 Parameters of cerebral vascular function (blood flow
Parameter Healthy volun
Right middle cerebral artery
Mean blood flow velocity (cm/s) 56.07 ±
Maximum blood flow velocity (cm/s) 87.58 ±
Pulsatility index 0.84 ±
Apnea Test (%) 56.79 ±
Left middle cerebral artery
Mean blood flow velocity (cm/s) 59.21 ±
Maximum blood flow velocity (cm/s) 94.30 ±
Pulsatility index 0.89 ±
Right anterior cerebral artery
Mean blood flow velocity (cm/s) 47.90 ±
Maximum blood flow velocity (cm/s) 75.97 ±
Pulsatility index 0.89 ±
Left anterior cerebral artery
Mean blood flow velocity (cm/s) 48.95 ±
Maximum blood flow velocity (cm/s) 76.66 ±
Pulsatility index 0.87 ±
Right posterior cerebral artery
Mean blood flow velocity (cm/s) 40.93 ±
Maximum blood flow velocity (cm/s) 64.85 ±
Pulsatility index 0.8897
Left posterior cerebral artery
Mean blood flow velocity (cm/s) 37.84 ±
Maximum blood flow velocity (cm/s) 59.41 ±
Pulsatility index 0.86 ±
Basilar artery
Mean blood flow velocity (cm/s) 41.60 ±
Maximum blood flow velocity (cm/s) 65.35 ±
Pulsatility index 0.86 ±
apnea test = breath-holding test. Data are means ± SD.lower vasomotor reactivity in patients with FD than in
the control group (Table 1).
Vascular remodelling
We did not find differences between groups in the thick-
ness (IMT) of both common carotid arteries nor in the dis-
tance between adventitial layers of these arteries (Table 2).
Interestingly, no atherosclerotic plaques were found in the
carotid arteries in any of the studied subjects.
Endothelial dysfunction
In the study of post-ischemic brachial vasodilation, we did
not find significant differences between groups in the per-
centage of dilation after 60 seconds (Table 2). However,
concerning serum levels of biomarkers for endothelialand cerebral vasomotor reactivity
teers (n = 17) Patients with FD (n = 10) p value
10.36 56.82 ± 15.53 0.9
16.48 86.64 ± 21.66 0.9
0.15 0.80 ± 0.18 0.57
15.68 47.25 ± 15.36 0.21
14.15 58.15 ± 16.95 0.9
22.09 88.85 ± 26.64 0.6
0.1402 0.83 ± 0.2161 0.4
11.82 49.18 ± 13.00 0.8
16.73 74.53 ± 25.22 0.9
0.11 0.84 ± 0.21 0.4
11.69 47.29 ± 16.57 0.8
15.13 70.61 ± 25.79 0.5
0.15 0.89 ± 0.23 0.8
8.22 37.80 ± 11.11 0.4
13.19 53.55 ± 18.00 0.1
± 0.23 0.7651 ± 0.20 0.2
5.12 37.60 ± 10.11 0.9
7.48 56.25 ± 17.09 0.5
0.13 0.83 ± 0.20 0.8
8.14 45.38 ± 12.90 0.4
12.52 64.02 ± 25.69 0.8
0.13 0.78 ± 0.20 0.3
Table 2 Parameters of systemic endothelial function and vascular remodelling
Parameter Healthy volunteers (n = 17) Patients with FD (n = 10) p value
IMT right common carotid artery (mm) 0.57 ± 0.07 0.60 ± 0.19 0.51
Distance between advential layers of right common carotid artery (mm) 6.25 ± 1.55 6.50 ± 0.91 0.71
IMT left common carotid artery (mm) 0.54 ± 0.94 0.62 ± 0.21 0.16
Distance between advential layers of left common carotid artery (mm) 6.45 ± 0.78 6.66 ± 0.91 0.62
Mean diameter of brachial artery (mm) 3.64 ± 0.67 3.38 ± 0.70 0.36
Brachial hyperaemic vasodilation test (60”) 16.85 ± 10.59 14.10 ± 11.62 0.54
us-CRP (mg/L) 1.74 ± 1.51 2.92 ± 1.88 0.14
IL-6 (pg/mL) 7.48 ± 2.15 6.34 ± 1.42 0.06
sVCAM-1 (ng/mL) 714.47 ± 178.22 899.50 ± 217.24 0.02
TNF-α (pg/mL) 4.41 ± 1.17 5.41 ± 1.66 0.11
IMT, intima-media thickness. Data are means ± SD. p < 0.05 compared to control patient.
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of IL-6 and high serum levels of sVCAM-1, TNF-α and
hs-CRP in Fabry patients than in healthy volunteers.
Notably, in the case of sVCAM-1, statistically significant
differences were observed (899.50 ng/mL in FD patients
vs 714.47 ng/mL in healthy volunteers, p = 0.02) (Table 2
and Figure 1).Figure 1 Charts showing mean values and 95% CIs of the plasma conce
VCAM (C) and TNF-alfa (D) in patients with Fabry disease (n = 10) and cDiscussion
The main clinical manifestations in FD consist of vascu-
lar associated complications, but the pathophysiology of
the FD vasculopathy is unclear. Specifically, the exact
nature of the cerebrovascular disease in FD is controver-
sial. It has been postulated that the accumulation of gly-
cosphyngolipids in the endothelium might increase thentration levels of high-sensitive CRP (hs-CRP) (A), IL-6 (B), soluble
ontrols (n = 17), matched for age and gender. * p < 0.05.
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clusion of the small vessels or indirectly by generating
endothelial dysfunction [14]. However, there is also the
possibility that the anomalous accumulation of glyco-
sphyngolipids may affect the muscle cells of the vessel
wall, and/or the vegetative neurons regulating them [19].
If this latter occurred, there would be a loss of the char-
acteristic special hemodynamics of the brain vessels, in-
cluding vasoreactivity [12,14,20]. Although it would be
expected that this disturbance only was able to affect
the smaller vessels of the brain, the fact is that previously
some authors had described the existence of hyperflow
[14,21] in the basal cerebral arteries, while others found
hypoflow [13]. In our study we have not found relevant
differences in the blood flow parameters of the main cere-
bral arteries between healthy volunteers and FD patients.
These findings may be related to the small sample size,
although the results did not show any trend. Secondly,
we studied if FD patients suffered any alteration of the
cerebral vasoreactivity. We only detect a trend toward a
lower vasomotor reactivity in the middle cerebral artery
of patients with FD. The cerebral vasomotor reactivity is
a control mechanism to regulate the brain blood supply
in an attempt to ensure that the metabolism of the brain
will not be affected by systemic alterations or arterial
pressure variations. It achieves its function by increasing
the blood flow through vasodilation of the cerebral arte-
rioles if the systemic pressure falls or the metabolic condi-
tions worsen. In fact, cerebrovascular reactivity damage
due to autonomic dysfunction has been previously con-
sidered among the pathogenic factors of thrombotic and
ischemic brain infarctions of FD [12,13], but in our group,
we were not able to confirm that hypothesis. Again, these
findings may be related to the small sample size or be in-
fluenced because the measures were taken at the middle
cerebral artery. Thus, a recent study [15], did find a dis-
turbed neurovascular coupling in the territory of the pos-
terior cerebral artery, which could translate a dysfunction
of cerebrovascular reactivity in the territory of that artery.
Our work was also designed to investigate whether ar-
terial remodelling could influence the high vascular risk
of Fabry patients. As such, we measured the inter-
adventicial caliber of the carotid arteries and the thick-
ness of the intima-media layer. We found no differences
between groups. It therefore seems unlikely that macro-
vascular damage in the extracranial bed could be re-
sponsible for the origin of cerebrovascular disease in
most Fabry patients, at least until advanced stages of
disease.
Finally, we also investigated the presence of endothe-
lial dysfunction. First, we used a test of proven value in
determining endothelial dysfunction, the brachial hyper-
aemic vasodilation test. We did not find relevant differ-
ences between patients and controls. Previous studiessuggested a chronic alteration of the nitric oxide (NO)
pathway in Fabry disease [14], but at the same time has
been shown that non-NO factors determine an enhanced
endothelium-dependent vasodilation in Fabry disease [22].
Thus, an event could compensate for another and the final
result may be a normal brachial hyperaemic vasodilation
test, as we found. Secondly, serological markers of in-
flammation and endothelial activation were measured.
Probably the most relevant finding of our study was that,
in absence of clear vascular remodelling or vasodilatadory
endothelial dysfunction, increased levels of endothelium-
release biomarkers (sVCAM-1, hs-CRP and TNF-α) were
observed in patients with FD. In the case of sVCAM-1,
the differences were statistically relevant. Previous studies
had also reported increased biomarker levels for endo-
thelial activation, such as sVCAM-1, sICAM, P-selectin,
E-selectin, plasminogen activator inhibitor (PAI) and
endothelium derived micro-particles [23-26], thus sug-
gesting that a local process in the vessel wall could be
primarily responsible for the ischemic lesions [19]. In an
in vitro study [25], an excess of intracellular accumula-
tion of Gb3 induced oxidative stress and up-regulated
the expression of cellular adhesion molecules (ICAM-1,
VCAM-1 and E-Selectin) in vascular endothelial cells of
FD patients. Reduction of endogenous Gb3 by treatment
of the cells with an inhibitor of glycosphingolipid synthase
or α-galactosidase A led to decreased expression of adhe-
sion molecules. At a clinical level, a study done investi-
gating 25 patients and 25 controls [23] showed increased
concentrations of sICAM-1, sVCAM-1, P-selectin and
PAI, and decreased levels of thrombomodulin in Fabry
patients, thus suggesting that endothelium activation
and a prothrombotic state may play a significant role
in the occurrence of stroke in Fabry disease. However,
in a subsequent study [24] no differences were found in
ICAM-1, plasma P-selectin or plasma thrombomodulin
levels between 12 patients and 15 controls, although
plasmatic levels of sVCAM-1 were also significantly higher
in patients with Fabry disease.
We also found higher levels of sVCAM-1, hs-CRP and
TNF-α in FD patients than in healthy volunteers and in
the case of sVCAM-1, the differences were statistically
relevant. The VCAM-1 molecule is inducible by cytokines
such as TNF-α, IL-1, and IL-4 on endothelium in vitro
[27]. VCAM-1 mediates the adhesion of immflamatory
cells to vascular endothelium and functions in leukocyte-
endothelial cell signal transduction [28]. For these reasons,
VCAM-1 is a valid candidate marker to measure endothe-
lial dysfunction in vivo, but its high levels should be con-
sidered as an indicator of systemic endothelial dysfunction
and not just a local phenomenon [19,29].
Our study has some limitations. First, the small size
of our sample. FD is a rare condition and it is difficult
to get a large number of patients to study (in Spain, for
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Then, a complete and centralized vascular study over 10
patients should be considered of interest. Another pos-
sible limitation of this study is the pooled analysis of data
from both homozygous and hemizygous FD patients
and from patients receiving ERT and untreated patients.
Nevertheless, in subanalyses performed only in homozy-
gous or hemizygous alone or in treated/untreated patients,
similar results were obtained (data not showed). Finally,
it has been proposed that the plasmatic abnormalities in
markers for endothelial activation were more likely re-
lated to renal insufficiency rather than to Fabry disease
itself [30]. However, in our sample only one patient had
advanced kidney disease, and both the remaining patients
and controls had a glomerular filtration rate within nor-
mal limits. Excluding this sole patient in the statistical
analysis did not change the differences between the groups
regarding to levels of sVCAM-1. In fact, the detected value
of sVCAM-1 in this patient was 662 ng/mL, below the
mean value of patients and controls.
Our findings support the hypothesis that an increased
endothelial inflammatory profile exists in Fabry disease
patients. This proinflammatory endothelial dysfunction
seems to be present in the early stages of the illness, be-
fore any sign of atheromatosis or arterial remodelling and
even before any relevant alteration of the endothelium-
dependent vasodilator capacity, and could be the main
cause of the thrombogenicity of FD. If so, then serum
biomarkers are probably better indicators than brain
hemodynamic parameters to estimate the stroke risk in
FD patients and to measure the efficacy of therapeutic
interventions in this field.
Our results do not help to explain the special affinity
of FD thrombogenicity by the brain. We cannot exclude
that in patients with advanced disease a clear deterior-
ation of cerebral hemodynamics could appear; that situ-
ation, coupled with the previous endothelial dysfunction
might then explain the predominant involvement of the
brain. To clarify this hypothesis, larger studies specially
focused in FD patients who have already had cerebral in-
volvement, are necessary.
Conclusions
In summary, the vasculopathy of Fabry disease has been
classically attributed to the progressive deposition of
Gb3 in the vascular endothelium, which could eventually
lead to structural abnormalities in the vessel wall; how-
ever, our results as well as other from previous studies,
allow us to hypothesize that the primary metabolic defect
could induce a cascade of events leading to endothelial
dysfunction that, with the progression of the disease,
might promote thrombotic phenomena and cerebrovas-
cular events. Serum biomarkers would then be probably
better indicators than brain hemodynamic parametersto estimate the stroke risk in Fabry disease and to meas-
ure the efficacy of therapeutic interventions in this field.
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